pink dots icon

Comprehensive Genomic Profiling (CGP) provides oncologists with the capability to identify a broader set of actionable targets, enables researchers to uncover new biomarkers, and allows pathologists to eliminate the need for sequential tests. However, unique challenges must be overcome to unlock those benefits, such as optimizing analytical performance*, facilitating interpretation, and providing secure data storage. The SOPHiA DDM™ Platform offers several features that simplify, expand, and accelerate the assessment of complex genomic variants covered by the Illumina’s TruSight™ Tumor 170 and TruSight™ Oncology 500 panels. CGP holds answers, SOPHiA DDM™ helps you get them.

Rely on highly optimized analytical performance*

Comprehensive genomic profiling simultaneously detects multiple genomic alterations across a broad panel of genes and derives valuable insights from this information. For experts to have confidence in their answers, SOPHiA DDM™ is optimized to detect SNVs, Indels, CNVs, Fusions accurately and, when applicable, to evaluate MSI and TMB. Our platform expands CNV coverage and broadens MSI and TMB measurement while providing access to all source files and quality reports for full traceability and quality control.

A universal health data analytics platform for a decentralized approach to healthcare

Fig.1 Comparison of SOPHiA DDM for TSO500 and SOPHiA DDM for TST170 fusion detection capabilities with standard solution – Based on analysis of 131 confirmed fusions from 105 clinical and reference samples (source: data on file)

A universal health data analytics platform for a decentralized approach to healthcare

Fig.2 Concordance with TSO500 LocalApp v2.2 comparing Mut/Mb in 64 samples, including 53 clinical FFPE tissue samples from more than 10 tumor types (source: data on file)

Focus on what matters

Comprehensive genomic profiling can deliver more insights and fewer missed opportunities than smaller panels. However, analyzing a large set of variants from a CGP test is a demanding endeavor. To overcome CGP challenge, SOPHiA DDM™ provides a streamlined FASTQ-to-report workflow that was designed to facilitate the interpretation process of all variants and biomarkers. Some of its key features include hotspot screening, customizable filters, variant pre-classification, and evidence-based decision support based on guidelines and scientific literature. Together these elements enable users to focus on relevant and actionable genomic alterations for a given cancer type. All features are seamlessly integrated into the user-friendly, intuitive environment of the SOPHiA DDM™ Platform.

A universal health data analytics platform for a decentralized approach to healthcare

Fig 3. Illustrative representation of SOPHiA DDM™ workflow from secondary analysis data to report

Have confidence in your workflow

When rapidity and reliability of answers matter – so are the concern for adoption, workflow disruptions, and compliance with data security policies. Whether institutions require support with the challenging adoption stages (sampling strategy, deploying bioinformatics infrastructure) or during the product’s lifecycle, our worldwide team of local experts supports institutions to minimize workflow disruption. Additionally, our solutions comply with global and regional data security policies and rely on quality reports and audit trails to offer workflows you can trust.

To fully access CGP benefits, efficiency, simplicity and confidence are essential. Our solutions are optimized to help unlock those benefits. Discover our comprehensive genomic profiling bioinformatics workflows.

pink dots icon

Want to know more?
Get in touch with us.

Our client services team is on hand to help.